Keller Graduate School of management
Makers of medical device implants and diagnostic products proved health care was no monolith after broadly outperforming the U.S. market and their health care brethren in 2018. But 2019 is shaping up quite differently through the first day of trading amid a spotlight from a variety of investment banks.
Increasing wariness in Washington over China’s investments in U.S. biotechnology companies may cool a hot source of capital for medical startups.
As equity investors caught up in the cannabis craze push pot stocks to record highs, options traders are paying the most ever to hedge against a comedown.
As Biogen Inc. prepares to kick off earnings season Tuesday for a beaten-down large-cap biotechnology sector, investors won’t be too focused on the financial results.
Amazon announced today that it has signed an agreement to acquire PillPack, an online pharmacy that offers pre-sorted doses of medications, home delivery, and a commitment to customer service
Philips (PHG.AS) is worried about rising trade tensions between the United States and China, said the Dutch health-technology company that is banking on continuing Chinese demand for its high-end medical equipment.
Equities have greeted 2018 with a bang, but none more so than Korean pharmaceutical maker Celltrion Inc., which has piled on about 9 trillion won ($8.4 billion) of market value in just seven days.
Pharm Exec's latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
